**MHDL Update**

Below are certain updates to the MassHealth Drug List (MHDL). See the MHDL for a complete listing of updates.

### Additions

Effective May 7, 2018, the following newly marketed drugs have been added to the MHDL.

- Aliqopa (copanlisib) – PA
- benznidazole
- Endari (l-glutamine) – PA
- Fasenra (benralizumab) – PA
- Mepsevii (vestronidase alfa-vjbk) – PA
- Parsabiv (etelcalcetide) ^
- Qvar Redihaler (beclomethasone MDI, breath-actuated) – PA
- Solosec (secnidazole) – PA
- Sublocade (buprenorphine extended-release injection) – PA
- Symdeko (tezacaftor/ivacaftor) – PA

---

**Updated MassHealth Brand Name Preferred Over Generic Drug List**

Effective May 7, 2018, the following agents will be added to the MassHealth Brand Name Preferred Over Generic Drug List.

- Prevacid Solutab (lansoprazole orally disintegrating tablet) BP – PA ≥ 2 years
- Remodulin (treprostinil injection) BP – PA
- Zavesca (miglustat) BP – PA

---

**Legend**

- **PA** Prior authorization is required. The prescriber must obtain prior authorization for the drug in order for the pharmacy to receive payment. Note: PA applies to both the brand-name and the FDA “A”-rated generic equivalent of listed product.
- **BP** Brand preferred over generic equivalents. In general, MassHealth requires a trial of the preferred drug or clinical rationale for prescribing the nonpreferred drug generic equivalent.
- ^ Available through the health care professional who administers the drug. MassHealth does not pay for this drug to be dispensed through a retail pharmacy.